Onset of action of formoterol versus salmeterol via dry powder inhalers in moderate chronic obstructive pulmonary disease: A randomized, placebo-controlled, double-blind, crossover study

Clinical Drug Investigation

Volumn 32, Issue 3, 2012, Pages 147-155

  Cazzola, Mario ^a,b   Paggiaro, Pierluigi ^c   Palange, Paolo ^d   Bjermer, Leif ^e   Ausin, Pilar ^f   Carlsson, Lars Goran ^g   Ekelund, Jan ^g   Lotvall, Jan ^h  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e LUND UNIVERSITY HOSPITAL   (Sweden)

^f INST MUNIC D INVESTIGACIO MEDICA   (Spain)

^g ASTRAZENECA R AND D   (Sweden)

^h UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

COPD; crossover; formoterol; onset of effect; salmeterol

Indexed keywords

FORMOTEROL; PLACEBO; SALMETEROL; TERBUTALINE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DISEASE SEVERITY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRY POWDER; EARDRUM PERFORATION; FEMALE; FEVER; FORCED EXPIRATORY VOLUME; GASTROENTERITIS; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINGLE DRUG DOSE; VIRAL RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRY POWDER INHALERS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84856871129     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11630880-000000000-00000     Document Type: Article

References (25)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2008 [online]. Available from [Accessed 2011 Nov 9]
2. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009; 25: 2043-8
3. Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/ formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009; 3: 1-11
4. Partridge MR, Miravitlles M, Stå hl E, et al. Development and validation of the Capacity of Daily Living during the Morning questionnaire and the Global Chest Symptoms Questionnaire in COPD. Eur Respir J 2010; 36: 96-104
5. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol 1994; 7: 103-7 (Pubitemid 24210802)
6. Cazzola M, Santus P, Di Marco F, et al. Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther 2004; 17: 121-5 (Pubitemid 38496186)
7. Celik G, Kayacan O, Beder S, et al. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999; 66: 434-9 (Pubitemid 29431577)
8. Cote C, Pearle JL, Sharafkhaneh A, et al. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther 2009; 22: 44-9
9. Kottakis J, Cioppa GD, Creemers J, et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 2002; 9: 107-15 (Pubitemid 34732669)
10. Lindberg A, Szalai Z, Pullerits T, et al. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 2007; 12: 732-9 (Pubitemid 47414887)
11. Richter K, Stenglein S, Mücke M, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration 2006; 73: 414-9
12. Benhamou D, Cuvelier A, Muir JF, et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 2001; 95: 817-21 (Pubitemid 33019578)
13. Cazzola M, Di Perna F, D'Amato M, et al. Formoterol Turbuhaler for as-needed therapy in patients with mild acute exacerbations of COPD. Respir Med 2001; 95: 917-21 (Pubitemid 33077129)
14. Bouros D, Kottakis J, Le Gros V, et al. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility. Curr Med Res Opin 2004; 20: 581-6 (Pubitemid 38685000)
15. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine induced severe bronchoconstriction. Eur Respir J 1999; 13: 988-92 (Pubitemid 29288919)
16. Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-9 (Pubitemid 28048620)
17. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008; 31: 416-69
18. Redelmeier DA, Goldstein RS, Min ST, et al. Spirometry and dyspnea in patients with COPD: when small differences mean little. Chest 1996; 109: 1163-8 (Pubitemid 26145650)
19. Make BJ. Chronic obstructive pulmonary disease: developing comprehensive management. Respir Care 2003; 48: 1225-34
20. Turner J, Wright E, Mendella L, et al. Predictors of patient adherence to long-term home nebulizer therapy for COPD. The IPPB Study Group. Intermittent Positive Pressure Breathing. Chest 1995; 108: 394-400
21. Cerveri I, Pellegrino R, Dore R, et al. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol 2000; 88: 1989-95 (Pubitemid 30453902)
22. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 16 (Suppl. 16): 5-40 (Pubitemid 23116782)
23. Sovani MP, Whale CI, Tattersfield AE. A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease. Drug Saf 2004; 27: 689-715 (Pubitemid 39158991)
24. Campbell M, Eliraz A, Johansson G, et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 2005; 99: 1511-20 (Pubitemid 41683932)
25. Cazzola M, Grella E, Matera MG, et al. Onset of action following formoterol Turbuhaler and salbutamol pMDI in reversible chronic airway obstruction. Pulm Pharmacol Ther 2002; 15: 97-102 (Pubitemid 34762146)